Alexion Pharmaceuticals said Wednesday it is buying Sweden’s Wilson Therapeutics for $855 million to expand its pipeline of drugs to treat rare diseases, as the pace of deal-making in the biotech sector ticks higher.
The centerpiece of the Alexion transaction is Wilson’s lead drug WTX101, an oral agent in Phase 3 development as a treatment for Wilson disease, a rare, inherited disorder that causes liver and neurologic problems. WTX101 works by binding to copper in the bloodstream and promoting its removal in the liver.
About the Author Reprints
